AnaptysBio Future Growth

Future criteria checks 2/6

AnaptysBio's earnings are forecast to decline at 10.7% per annum while its annual revenue is expected to grow at 32.7% per year. EPS is expected to grow by 2.3% per annum.

Key information

-10.7%

Earnings growth rate

2.3%

EPS growth rate

Biotechs earnings growth	21.1%
Revenue growth rate	32.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	16 Apr 2024

Recent future growth updates

Recent updates

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

Mar 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 28

Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth

Feb 10

Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters

Dec 19

AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside

Nov 30

AnaptysBio (ANAB) Investor Presentation - Slideshow

Nov 18

Earnings and Revenue Growth Forecasts

NasdaqGS:ANAB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	28	-227	-270	-203	7
12/31/2025	26	-196	-131	-158	11
12/31/2024	16	-178	-79	-149	11
12/31/2023	17	-164	-122	-121	N/A
9/30/2023	15	-148	-98	-97	N/A
6/30/2023	13	-144	-79	-78	N/A
3/31/2023	11	-137	-78	-77	N/A
12/31/2022	10	-129	-74	-74	N/A
9/30/2022	4	-135	-88	-88	N/A
6/30/2022	24	-108	-78	-77	N/A
3/31/2022	53	-76	-45	-44	N/A
12/31/2021	63	-58	-47	-46	N/A
9/30/2021	122	8	15	17	N/A
6/30/2021	101	-9	5	7	N/A
3/31/2021	71	-30	-23	-22	N/A
12/31/2020	75	-20	-15	-14	N/A
9/30/2020	18	-74	-68	-68	N/A
6/30/2020	18	-81	-73	-73	N/A
3/31/2020	23	-84	-69	-69	N/A
12/31/2019	8	-97	-70	-70	N/A
9/30/2019	5	-94	-67	-66	N/A
6/30/2019	10	-79	-60	-59	N/A
3/31/2019	5	-69	-53	-52	N/A
12/31/2018	5	-62	-50	-49	N/A
9/30/2018	8	-52	-42	-41	N/A
6/30/2018	3	-45	-31	-30	N/A
3/31/2018	10	-34	-24	-24	N/A
12/31/2017	10	-30	-20	-19	N/A
9/30/2017	10	-27	N/A	-20	N/A
6/30/2017	13	-19	N/A	-19	N/A
3/31/2017	12	-15	N/A	-15	N/A
12/31/2016	17	-4	N/A	-9	N/A
9/30/2016	18	-4	N/A	-6	N/A
6/30/2016	19	-4	N/A	-5	N/A
3/31/2016	18	-6	N/A	-9	N/A
12/31/2015	18	-5	N/A	-10	N/A
9/30/2015	17	-2	N/A	-6	N/A
6/30/2015	19	0	N/A	-4	N/A
3/31/2015	18	1	N/A	-3	N/A
12/31/2014	16	0	N/A	15	N/A
12/31/2013	5	-6	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANAB's revenue (32.7% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: ANAB's revenue (32.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANAB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

AnaptysBio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 48%

No longer forecast to breakeven

Price target increased by 27% to US$35.83

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

Consensus revenue estimates increase by 16%

Recent updates

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 16%

Price target decreased by 10% to US$26.80

Price target decreased by 12% to US$28.20

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates decrease by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 43%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2025

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Consensus forecasts updated

Price target increased to US$31.50

Price target increased to US$31.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Consensus revenue estimates increase by 58%

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Consensus revenue estimates increase by 17%

Price target decreased to US$29.33

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Consensus revenue estimates fall by 10%

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

High number of new directors

COO & General Counsel notifies of intention to sell stock

Price target decreased to US$31.60

Consensus revenue estimates fall by 56%

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Forecast to breakeven in 2024

Consensus revenue estimates increase by 86%

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Consensus revenue estimates fall by 65%

Full year 2021 earnings: EPS and revenues miss analyst expectations

President notifies of intention to sell stock

Consensus EPS estimates increase to US$0.84

Consensus revenue estimates increase to US$138.2m

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Price target increased to US$35.71